Art

J-GLOBAL ID：201302238885971157   Reference number：13A1826516

Limited Sampling Strategy for the Estimation of Mycophenolic Acid Area under the Concentration-Time Curve Treated in Japanese Living-Related Renal Transplant Recipients with Concomitant Extended-Release Tacrolimus

日本人生体腎移植患者における徐放性タクロリムスと併用したミコフェノール酸の血中濃度曲線下面積を推定するための限定標本抽出法

Author (11)： YAMAGUCHI Kazunori (Dep. of Pharmacy, Kagawa Univ. Hospital) ,  FUKUOKA Noriyasu (Dep. of Pharmacy, Kagawa Univ. Hospital) ,  KIMURA Sumio (Dep. of Pharmacy, Kagawa Univ. Hospital) ,  WATANABE Masahiro (Dep. of Pharmacy, Kagawa Univ. Hospital) ,  TANI Kumiko (Dep. of Pharmacy, Kagawa Univ. Hospital) ,  TANAKA Hiroaki (Dep. of Pharmacy, Kagawa Univ. Hospital) ,  SOFUE Tadashi (Dep. of Cardiorenal and Cerebrovascular Medicine, Fac. of Medicine, Kagawa Univ.) ,  KOSAKA Shinji (Dep. of Pharmacy, Kagawa Univ. Hospital) ,  INUI Masashi (Dep. of Urology, Tokyo Women’s Medical Univ.) ,  KAKEHI Yoshiyuki (Dep. of Urology, Fac. of Medicine, Kagawa Univ.) ,  HOUCHI Hitoshi (Dep. of Pharmacy, Kagawa Univ. Hospital)
Material： Biological and Pharmaceutical Bulletin  (Biological & Pharmaceutical Bulletin)
Volume： 36  Issue： 6  Page： 1036-1039 (J-STAGE)  Publication year： 2013 
JST Material Number： S0989A  ISSN： 0918-6158  CODEN： BPBLEO  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： *living renal transplantation

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=13A1826516&from=J-GLOBAL&jstjournalNo=S0989A") }}

JST classification (2)： Surgical treatment for urogenital diseases  (GM05030G) ,  Basic research of immunotherapeutic agents and blood preparations  (GW22010D)

Substance index (3)： Tacrolimus ,  Mycophenolic Acid ,  Mofetil mycophenolate

Reference (18)：

• 1) Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology, 47, 85窶錀118 (2000).
• 2) Gaston RS, Kaplan B, Shah T, Cibrik D, Shaw LM, Angelis M, Mulgaonkar S, Meier-Kriesche HU, Patel D, Bloom RD. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am. J. Transplant., 9, 1607窶錀1619 (2009).
• 3) Le Meur Y, Buchler M, Thierry A, Caillard S, Villemain F, Lavaud S, Etienne I, Westeel PF, Hurault de Ligny B, Rostaing L, Thervet E, Szelag JC, Rerolle JP, Rousseau A, Touchard G, Marquet P. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am. J. Transplant., 7, 2496窶錀2503 (2007).
• 4) van Gelder T, Tedesco Silva H, de Fijter JW, Budde K, Kuypers D, Arns W, Soulillou JP, Kanellis J, Zelvys A, Ekberg H, Holzer H, Rostaing L, Mamelok RD. Renal transplant patients at high risk of acute rejection benefit from adequate exposure to mycophenolic acid. Transplantation, 89, 595窶錀599 (2010).
• 5) van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, Holt DW, Kaplan B, Kuypers D, Meiser B, Toenshoff B, Mamelok RD. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther. Drug Monit., 28, 145窶錀154 (2006).

Terms in the title (9)： 日本人 ,  生体腎移植 ,  患者 ,  徐放性 ,  タクロリムス ,  併用 ,  ミコフェノール酸 ,  血中濃度曲線下面積 ,  推定